N-(5-(5-(5,5-dimethyl-4-hydroxy-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,6-difluorobenzamide | 1373939-41-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-(5-(5,5-dimethyl-4-hydroxy-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,6-difluorobenzamide
• 英文别名: (R/S)-N-(5-(5-(5,5-Dimethyl-4-hydroxy-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,6-difluorobenzamide；2,6-difluoro-N-[5-[5-(4-hydroxy-5,5-dimethyl-4H-1,2-oxazol-3-yl)-2-methylphenyl]pyrazin-2-yl]benzamide
• CAS: 1373939-41-3
• 化学式: C₂₃H₂₀F₂N₄O₃
• 分子量: 438.434
• InChiKey: LARRWNWCNNWGKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  96.7
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-(3-bromo-4-methylphenyl)-5,5-dimethyl-4,5-dihydroisoxazol-4-ol 在 bis-triphenylphosphine-palladium(II) chloride 、 palladium bis[bis(diphenylphosphino)ferrocene] dichloride chromium(VI) oxide 、 甲醇 、 sodium tetrahydroborate 、 硫酸 、 potassium acetate 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 、 溶剂黄146 为溶剂， 反应 24.67h， 生成 N-(5-(5-(5,5-dimethyl-4-hydroxy-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,6-difluorobenzamide
  参考文献：
  名称：

  [EN] OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS
  [FR] MODULATEURS DE CANAUX CRAC À BASE D'OXAZOLE ET D'ISOXAZOLE

  摘要：

  公开号：

  WO2012056478A8

文献信息

• OXAZOLE AND ISOXAZOLE CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20160022673A1

  公开（公告）日：2016-01-28

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及公式（I）的化合物及其制备方法，用于治疗、预防和/或管理与CRAC调节相关的疾病、疾病、综合征或病况。本发明还涉及使用公式（I）的方法来治疗、预防、管理和/或减轻与CRAC调节相关的疾病、疾病、综合征或病况。
• OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS
  申请人：Lupin Limited

  公开号：EP3067347A1

  公开（公告）日：2016-09-14

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及式(I)化合物及其制备工艺，它们可用于治疗、预防和/或控制与CRAC调节有关的疾病、失调、综合征或病症。本发明进一步涉及治疗、预防、控制和/或减轻与调节式（I）CRAC 相关的疾病、失调、综合症或病症的方法。
• Oxazoline and isoxazoline derivatives as CRAC modulators
  申请人：LUPIN LIMITED

  公开号：US10292981B2

  公开（公告）日：2019-05-21

  The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及式（I）化合物、 及其制备工艺，可用于治疗、预防和/或控制与调节 CRAC 有关的疾病、失调、综合征或病症。本发明进一步涉及治疗、预防、控制和/或减轻与式（I）的 CRAC 调节相关的疾病、失调、综合症或病症的方法。
• US9169242B2
  申请人：——

  公开号：US9169242B2

  公开（公告）日：2015-10-27
• US9737534B2
  申请人：——

  公开号：US9737534B2

  公开（公告）日：2017-08-22